Esperion TherapeuticsESPR
About: Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Employees: 240
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
32% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 25
30% more capital invested
Capital invested by funds: $214M [Q3] → $277M (+$63.3M) [Q4]
26% more call options, than puts
Call options by funds: $5.22M | Put options by funds: $4.13M
22% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 45
3% more funds holding
Funds holding: 182 [Q3] → 188 (+6) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
1.73% less ownership
Funds ownership: 68.23% [Q3] → 66.5% (-1.73%) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Needham Serge Belanger 30% 1-year accuracy 39 / 129 met price target | 376%upside $5 | Buy Reiterated | 8 Apr 2025 |
HC Wainwright & Co. Joseph Pantginis 11% 1-year accuracy 47 / 423 met price target | 1,424%upside $16 | Buy Reiterated | 20 Mar 2025 |
Citizens Capital Markets Jason Butler 50% 1-year accuracy 2 / 4 met price target | 281%upside $4 | Market Outperform Reiterated | 5 Mar 2025 |
JMP Securities Roy Buchanan 13% 1-year accuracy 3 / 24 met price target | 281%upside $4 | Market Outperform Reiterated | 11 Feb 2025 |
Financial journalist opinion
